It’s no secret that big pharmaceutical companies like $Eli Lilly(LLY)$ need to get regulators to agree that their drugs are safe and effective before they can make money. But regulators aren’t the only group companies need to appease before shareholders see returns.On October 23, Eli Lilly’s Alzheimer’s drug Kisunla was approved in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA), following in the footsteps of the US Food and Drug Administration (FDA) and Japanese regulators. UK regulators agreed with clinical trial results that showed the drug was somewhat effective in slowing or stopping the rate of cognitive decline associated with the disease for up to about seven months. They also found that treatment-related side effects,

In August 2011, just a few years after the financial crisis, Standard & Poor’s downgraded the U.S. credit rating from AAA (the highest rating) to AA+ (the second highest). Then, in August 2023, Fitch followed suit, lowering the U.S. from AAA to AA+. Both S&P and Fitch still see the U.S. as having an extremely low risk of default, but that top-tier status is undeniably gone.Many U.S. companies have faced a similar fate. Back in 1980, around 60 publicly traded companies held AAA credit ratings. After more than four decades of acquisitions, mergers, bankruptcies, innovation, and economic shifts, only two companies still hold this perfect rating: tech giant $Microsoft(MSFT)$ and healthcare powerhouse $John

In the stock market, you don’t need to bet everything on expensive stocks to invest in quality companies. There are still solid options available at reasonable prices, like $Exelixis(EXEL)$ , which is currently trading below $40.Major Wins for ExelixisExelixis is a biotechnology company focused on oncology, with its most important product being Cabometyx, used to treat renal cell carcinoma (a type of kidney cancer) and hepatocellular carcinoma (liver cancer).Cabometyx has been the cornerstone of Exelixis’s revenue for some time. In Q2, its revenue grew 35.6% year-over-year, reaching $637.2 million. Cabometyx alone accounted for $437.6 million in the U.S., making up nearly 69% of the company's total revenue.While relying heavily on one product carr

Ryan_Z0528: +175% on $OKLO in 22 Days , The electricity value train：https://x.com/EricFlaningam/status/1848009956961685536 Investors are flocking to power-related stocks, and California-based advanced nuclear systems developer $Oklo Inc.(OKLO)$ has seen its stock price double, skyrocketing by 115% to a record high of $19.72, peaking at $20.64 and giving it a market cap of over $2.4 billion.Oklo went public in May through a merger with the special purpose acquisition company (SPAC) AltC Acquisition, experiencing volatile stock movements since then. The nuclear stock had fallen to a low of $5.35 on September 9 but has jumped over 200% in the past six weeks.Oklo is working on developing small modular reactors (SMRs) and plans to deliver its first rea

The GLP-1 weight-loss drug market is massive, but the competition is fierce. Instead of joining the race, Swiss pharma giant $Novartis AG(NVS)$ is playing it smart, focusing on more strategic growth areas.Novartis is sticking to what it’s good atCEO Vas Narasimhan recently said in an interview that the company has no plans to jump into the "crazy" weight-loss market, claiming they’ve got better options. He’s aiming to invest in projects with bigger potential payoffs, like radioligand cancer therapies, which could bring in up to $20 billion.Novartis is also eyeing other opportunities in treatments for Parkinson's, Huntington's, and Alzheimer’s diseases. Compared to the ultra-competitive weight-loss field, these areas might offer more solid ground fo

$Eli Lilly(LLY)$ is now one of the most valuable healthcare companies globally, boasting a market cap of over $800 billion. With its stock price surging more than 50% in the past 12 months, some investors may feel hesitant due to its price-to-earnings (P/E) ratio exceeding 100 times. However, there are strong reasons to consider Eli Lilly despite the high valuation. Here are three factors that suggest its valuation could continue to climb in the coming months and years:1. Tirzepatide's Undervalued PotentialEli Lilly has seen major success with FDA approvals, notably for the weight-loss drug Zepbound and the diabetes drug Mounjaro, both containing the same active ingredient: tirzepatide. These drugs are in the early stages of their growth cycles, an

Historically, small-cap stocks have thrived once the Fed begins cutting rates. Globally, markets in Japan, China, and the UK currently offer attractive valuations, providing interesting opportunities for investors.Small and Mid-Cap Stocks: Poised for GainsAccording to Brian G. Belski, chief investment strategist at BMO Capital Markets, valuations for small-cap and mid-cap stocks are appealing for investors looking to increase exposure. Data shows that small-cap stocks (S&P SmallCap 600) are still trading below their 20-year average, while mid-cap stocks (S&P MidCap 400) are only slightly above it. In contrast, the $.SPX(.SPX)$ is trading well above its 20-year average.Since 1995, in the year following the Fed’s first rate cut, the S&P

As the $.SPX(.SPX)$ approaches its all-time high, some undervalued components like $Pfizer(PFE)$ $AbbVie(ABBV)$ are flying under the radar. Both of these healthcare stocks boast dividend yields over 3% and are poised for further increases, making them likely candidates to outperform the S&P 500 in the next decade.1. $Pfizer(PFE)$Last December, Pfizer raised its dividend for the 15th consecutive year, with a current yield of 5.8%. Even without additional hikes, this stock can provide substantial passive income. With many new patented drugs in the pipeline, investors can reasonably expect steady quarterly dividend increa

In the long run, dividend-paying stocks often outperform non-dividend-paying companies. Over the 50 years, the average annual return for non-dividend stocks in the $S&P 500(.SPX)$ was just 4.27%, while dividend stocks delivered an average annual return of 9.17%.In Q2, hedge funds managed by billionaires Israel Englander and Igor Tulchinsky made significant purchases of shares in $AbbVie(ABBV)$ , a dividend-paying pharmaceutical giant. Englander's Millennium Management fund increased its stake in AbbVie by 682% (about 854,846 shares), while Tulchinsky's Worldquant Millennium Advisors established a new position with a purchase of 229,419 shares.With net worths exceeding $1 billion each, what motivated T

As investors scramble to seize new opportunities, China’s stock market surge is shaking up global portfolios. Market analysts say that with China rolling out aggressive economic stimulus, funds that previously favored Japanese and Southeast Asian stocks are now reversing course.Investors Flock to China as Stock Market SurgesStocks in markets like South Korea, Indonesia, Malaysia, and Thailand have seen net outflows. BNP Paribas even reported that over $20 billion has flowed out of Japan’s stock market in just the first few weeks of September.This shift could signal the end of strong performances for Asian markets outside of China. Earlier this year, India’s stock market soared on accelerating economic growth, and Southeast Asia was boosted by U.S. interest rate cuts, which helped regional

After a three-month delay, $Tesla Motors(TSLA)$ 's highly anticipated Robotaxi unveiling is just two weeks away. This is a high-stakes game that no one can afford to lose. Autonomous taxis are the backbone of Tesla's driverless plan, so October 10th might just shape the future of Musk's EV empire. Now, let's dive into why this day is so crucial for Tesla.What's happening on October 10th?Loads of car manufacturers are keen on developing autonomous vehicles. Tesla's been working on its Full Self-Driving (FSD) platform for years, and on October 10th, the world might finally see how this technology will steer the company's future. They've dubbed this event "We, Robot."Why is the Robotaxi unveiling such a big deal for Tesla?Well, it was originally set